{rfName}
Ad

Indexed in

License and use

Citations

3

Altmetrics

Grant support

The authors have been supported by the Spanish Ministry of Science and Innovation [RTI2018-094584-B-I00] and was cofounded by the European Regional Development Fund (ERDF) and the CERCA program from Generalitat de Catalunya, Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) [CB16/12/00334] and Generalitat de Catalunya [2017 SGR 1009]. H Playa-Albinyana is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities [FPU19/03110].

Analysis of institutional authors

Playà-Albinyana HAuthorArenas FAuthorColomer DCorresponding Author

Share

June 7, 2021
Publications
>
Editorial Material
No

Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery

Publicated to:Expert Opinion On Drug Discovery. 16 (10): 1085-1090 - 2021-10-03 16(10), DOI: 10.1080/17460441.2021.1935860

Authors: Playa-Albinyana, Heribert; Arenas, Fabian; Colomer, Dolors

Affiliations

‎ Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain - Author
‎ Inst Invest Biomed August Pi & Sunyer IDIBAPS, Expt Therapeut Lymphoid Malignancies Grp, Barcelona, Spain - Author
‎ Univ Barcelona, IDIBAPS, Hosp Clin, Hematopathol Unit,Dept Pathol, Barcelona, Spain - Author

Abstract

Keywords

biologycelllocuspathogenesispatient-derived xenograft (pdx) modelstcl1tcl1 mouse modeltransgenic mousetransgenic mouse modelsAnimalsBiologyCellChronic lymphocytic leukemia (cll)Disease models, animalDrug discoveryLeukemia, lymphocytic, chronic, b-cellLocusMiceMice, transgenicPathogenesisPatient-derived xenograft (pdx) modelsTcl1Tcl1 mouse modelTransgenic mouseTransgenic mouse modelsXenograft models

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Expert Opinion On Drug Discovery due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 30/279, thus managing to position itself as a Q1 (Primer Cuartil), in the category Pharmacology & Pharmacy.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-07-16:

  • WoS: 1
  • Scopus: 1
  • Europe PMC: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 13.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 13 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.1.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Mali.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Playà Albinyana, Heribert) and Last Author (Colomer Pujol, Dolors).

the author responsible for correspondence tasks has been Colomer Pujol, Dolors.